231 related articles for article (PubMed ID: 33812443)
21. [Outcomes of primary central nervous system lymphoma patients treated with high-dose methotrexate and rituximab].
Shiota Y; Dobashi N; Ito Y; Hosoba R; Yamauchi H; Ishii H; Nakano A; Fukushima R; Ohba R; Yahagi Y; Usui N; Yano S
Rinsho Ketsueki; 2019; 60(2):87-92. PubMed ID: 30842385
[TBL] [Abstract][Full Text] [Related]
22. Primary central nervous system lymphoma: status and advances in diagnosis, molecular pathogenesis, and treatment.
Zhang Y; Zhou DB
Chin Med J (Engl); 2020 Jun; 133(12):1462-1469. PubMed ID: 32452898
[TBL] [Abstract][Full Text] [Related]
23. Primary Central Nervous System Lymphoma.
Sinicrope K; Batchelor T
Neurol Clin; 2018 Aug; 36(3):517-532. PubMed ID: 30072069
[TBL] [Abstract][Full Text] [Related]
24. Central Nervous System Lymphoma: Novel Therapies.
Fortin Ensign SP; Gathers D; Wiedmeier JE; Mrugala MM
Curr Treat Options Oncol; 2022 Jan; 23(1):117-136. PubMed ID: 35182298
[TBL] [Abstract][Full Text] [Related]
25. Primary Central Nervous System Lymphoma: Clinical Characteristics, Treatment Options and Therapeutic Outcome in 36 Patients. A Single Center Experience.
Zektser M; Rabinovich A; Grinbaum U; Porges T; Gozlan A; Gourevitch A; Al-Athamen K; Barrett O; Peles I; Kaisman-Elbaz T; Levi E
Isr Med Assoc J; 2022 Oct; 24(10):654-660. PubMed ID: 36309861
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic management of refractory or relapsed primary central nervous system lymphomas.
Reni M; Ferreri AJ
Ann Hematol; 2001; 80 Suppl 3():B113-7. PubMed ID: 11757691
[TBL] [Abstract][Full Text] [Related]
27. The outcome of ibrutinib-based regimens in relapsed/refractory central nervous system lymphoma and the potential impact of genomic variants.
Wang S; Zhu Y; Qian X; Ding T; Yuan Y; Li Y; Wu H; Chen T
Adv Clin Exp Med; 2023 Aug; 32(8):855-863. PubMed ID: 36881367
[TBL] [Abstract][Full Text] [Related]
28. Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma.
Grommes C; Tang SS; Wolfe J; Kaley TJ; Daras M; Pentsova EI; Piotrowski AF; Stone J; Lin A; Nolan CP; Manne M; Codega P; Campos C; Viale A; Thomas AA; Berger MF; Hatzoglou V; Reiner AS; Panageas KS; DeAngelis LM; Mellinghoff IK
Blood; 2019 Jan; 133(5):436-445. PubMed ID: 30567753
[TBL] [Abstract][Full Text] [Related]
29. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
Abrey LE; Moskowitz CH; Mason WP; Crump M; Stewart D; Forsyth P; Paleologos N; Correa DD; Anderson ND; Caron D; Zelenetz A; Nimer SD; DeAngelis LM
J Clin Oncol; 2003 Nov; 21(22):4151-6. PubMed ID: 14615443
[TBL] [Abstract][Full Text] [Related]
30. Successful treatment of non-Hodgkin's lymphoma of the central nervous system with BMPD chemotherapy followed by radiotherapy.
Korfel A; Thiel E
Leuk Lymphoma; 1998 Aug; 30(5-6):609-17. PubMed ID: 9711923
[TBL] [Abstract][Full Text] [Related]
31. New approaches in primary central nervous system lymphoma.
Fraser E; Gruenberg K; Rubenstein JL
Chin Clin Oncol; 2015 Mar; 4(1):11. PubMed ID: 25841718
[TBL] [Abstract][Full Text] [Related]
32. Review of rituximab in primary CNS lymphoma.
Singh PK; Pan E
J Neurol Sci; 2020 Mar; 410():116649. PubMed ID: 31901591
[TBL] [Abstract][Full Text] [Related]
33. Introduction of novel agents in the treatment of primary CNS lymphoma.
Grommes C; Nayak L; Tun HW; Batchelor TT
Neuro Oncol; 2019 Feb; 21(3):306-313. PubMed ID: 30423172
[TBL] [Abstract][Full Text] [Related]
34. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
[TBL] [Abstract][Full Text] [Related]
35. Temozolomide for relapsed primary CNS lymphoma.
Osmani AH; Masood N
J Coll Physicians Surg Pak; 2012 Sep; 22(9):594-5. PubMed ID: 22980617
[TBL] [Abstract][Full Text] [Related]
36. [Medical management of primary central nervous system lymphoma refractory or resistant to standard of care treatment].
Yamanaka R
Brain Nerve; 2009 Oct; 61(10):1155-64. PubMed ID: 19882942
[TBL] [Abstract][Full Text] [Related]
37. Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly.
Fritsch K; Kasenda B; Hader C; Nikkhah G; Prinz M; Haug V; Haug S; Ihorst G; Finke J; Illerhaus G
Ann Oncol; 2011 Sep; 22(9):2080-2085. PubMed ID: 21303800
[TBL] [Abstract][Full Text] [Related]
38. High-dose methotrexate monotherapy for newly diagnosed primary central nervous system lymphoma: 15-year multicenter experience.
Yoon WS; Park JS; Kim YI; Chung DS; Jeun SS; Hong YK; Yang SH
Asia Pac J Clin Oncol; 2021 Feb; 17(1):123-130. PubMed ID: 32978898
[TBL] [Abstract][Full Text] [Related]
39. Bruton's tyrosine kinase (BTK) inhibitors for the treatment of primary central nervous system lymphoma (PCNSL): current progress and latest advances.
Schaff L; Nayak L; Grommes C
Leuk Lymphoma; 2024 Apr; ():1-13. PubMed ID: 38597202
[TBL] [Abstract][Full Text] [Related]
40. Diagnosis and management of primary central nervous system lymphoma.
Han CH; Batchelor TT
Cancer; 2017 Nov; 123(22):4314-4324. PubMed ID: 28950405
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
